The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
{{output}}
AT13387 is an orally bioavailable clinical candidate developed to inhibit theheat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, ... ...
